- About Parkinson's disease
- Product profile
- Development to date
- Future development
LCT 0.019 Last updated EOD 17th February 2020
The following fact sheets provide a summary of our current business and research pipeline.
Future development path
At 24 months post implant the 4 people with Parkinson’s disease who received 80 capsules continue to show a benefit as measured by the change in the Unified Parkinson’s Disease Rating Scale (UPDRS Part III in the off state). This was greater than the 2 placebo group in that section of the Trial, but not when compared to all the 6 placebo patients (4 from the other groups) in whom responses were quite varied. Recipients of 40 capsules showed no difference from placebo.
Two years after NTCELL implantation, the criteria of a successful Phase IIb trial were met: safety and dose responsive efficacy compared to a placebo group. Although successful, the small numbers in the trial necessitate a confirmative larger Phase III study. With specialist input from our expert Medical Advisory Board, we are exploring the feasibility of a further study as it would require additional resources and clinical study design.
Our medical advisory board members are:
Professor Roger Barker (Chairman)
Professor of Clinical Neuroscience and Honorary Consultant in Neurology at the University of Cambridge and at Addenbrooke's Hospital.
Professor Barker combines basic research looking at novel therapies to treat chronic neurodegenerative disorders of the brain with clinically-based work aimed at better defining such disorders. He is the co-ordinator of the TRANSEURO project looking at fetal cell grafting in patients with early Parkinson’s disease and is part of the GFORCE PD initiative as well as director of the ISSCR.
Dr. Patrik Brundin
Professor and Director of the Center for Neurodegenerative Science, VARI Associate Director of Research and Jay Van Andel Endowed Chair in Parkinson’s Research, Grand Rapids, Michigan.
Dr. Brundin has 35 years’ experience studying neurodegenerative diseases, Parkinson’s disease pathogenesis and therapeutic neural transplantation into people with Parkinson’s. His current research focuses on pathogenic mechanisms of Parkinson’s disease as well as the development of new therapies that slow or stop disease progression or that repair damaged brain circuits.
Professor Thomas Foltynie
Professor of Neurology in the Department of Clinical and Movement Neurosciences, UCL Institute of Neurology and Consultant Neurologist at the National Hospital for Neurology and Neurosurgery, Queen Square, London.
Professor Foltynie is responsible for movement disorder patients, particularly Parkinson’s disease patients undergoing advanced treatments such as Deep Brain Stimulation (DBS), Apomorphine and Duodopa.
Professor Carolyn Sue
Director of Neurogenetics at Royal North Shore Hospital and the Director of the Kolling Institute, University of Sydney.
Professor Sue is an international expert in mitochondrial disease and movement disorders. Her research focuses on understanding the role of mitochondrial function in neurodegeneration, especially the disease processes involved in mitochondrial disorders, Parkinson’s disease and other movement disorders.
Dr Barry Snow
Director of Adult Medicine and Consultant Neurologis at Auckland District Health Board.
In addition to his general Neurology work, Dr Snow runs a Movement Disorder Clinic and research programme. He is the Principal Investigator in the clinical studies of NTCELL in Parkinson's disease.